When is fibrinogen measurement indicated and what are the management strategies for hypo‑fibrinogenemia and hyper‑fibrinogenemia?

Fibrinogen Measurement and Management

When to Measure Fibrinogen

Measure fibrinogen immediately in any patient with active major bleeding, particularly in trauma, massive transfusion, postpartum hemorrhage, cardiac surgery, or disseminated intravascular coagulation. 1

Specific Clinical Indications:

• Major trauma with ongoing bleeding – fibrinogen is the first coagulation factor to reach critically low levels during massive hemorrhage 1, 2
• Postpartum hemorrhage – fibrinogen <2.0 g/L has 100% positive predictive value for progression to severe bleeding 1
• Cardiac surgery with microvascular bleeding – particularly when guided by viscoelastic testing 1
• Massive transfusion protocols – measure at baseline and serially (every 12-24 hours during active bleeding) 1
• Suspected congenital fibrinogen disorders – measure baseline levels and differentiate with functional vs. antigenic assays 1, 3
• Acute coronary syndromes – elevated fibrinogen is an independent predictor of mortality and recurrent MI 4, 5

Measurement Methods:

• Clauss assay is the gold standard for functional fibrinogen measurement in all clinical scenarios 6, 3, 2
• Viscoelastic testing (ROTEM FIBTEM or TEG) is preferred in emergency settings for real-time assessment, providing 30-60 minute time advantage over laboratory testing 6, 7
• Important caveat: Hydroxyethyl starch (HES) causes significant overestimation of fibrinogen by the Clauss method 1, 4

---

Management of Hypofibrinogenemia

In actively bleeding patients with fibrinogen <1.5 g/L, immediately administer fibrinogen concentrate 3-4 g IV or cryoprecipitate 15-20 units (50 mg/kg), guided by viscoelastic testing when available. 1, 6

Treatment Thresholds by Clinical Context:

Major Trauma/Massive Hemorrhage:

• Target: ≥1.5 g/L 1, 2
• Initial dose: fibrinogen concentrate 3-4 g OR cryoprecipitate 50 mg/kg (15-20 units in 70 kg adult) 1, 8
• Repeat doses guided by viscoelastic monitoring or laboratory fibrinogen levels 1, 6

Obstetric Hemorrhage:

• Target: ≥2.0 g/L (higher threshold than other bleeding scenarios) 1, 8
• Maintain this level throughout active bleeding and for 3 days post-vaginal delivery, 5 days post-cesarean 1
• Add tranexamic acid for prophylaxis depending on thrombotic risk 1

Cardiac Surgery:

• Target: ≥1.5 g/L 1
• Empiric fibrinogen concentrate (1-4 g) reduces blood loss and transfusion requirements without increasing thrombotic complications 1
• Viscoelastic-guided dosing (FIBTEM MCF >9 mm) is preferred over fixed dosing 1, 6

Disseminated Intravascular Coagulation (DIC):

• Treat when fibrinogen <1.0 g/L in the presence of bleeding 1, 8

Advanced Liver Disease:

• Maintain >1.0 g/L only in actively bleeding patients 1, 8
• Routine correction in non-bleeding cirrhotic patients is not recommended 6

Viscoelastic-Guided Replacement Algorithm:

For bleeding patients with available ROTEM/TEG: 6

1. FIBTEM MCF ≤4-6 mm (≈ fibrinogen ≤1.5 g/L) → Strong indication for immediate replacement
2. FIBTEM MCF 6-8 mm → Consider replacement if ongoing significant microvascular bleeding
3. Target FIBTEM MCF >9 mm (≈ fibrinogen >1.5 g/L)
4. Avoid FIBTEM MCF >14 mm – supranormal levels provide no benefit and may increase thrombotic risk

Product Selection:

Fibrinogen concentrate is preferred over cryoprecipitate when available due to standardized dosing, viral inactivation, no cross-matching requirement, and easier logistics. 1, 8, 6

• Fibrinogen concentrate: 3-4 g IV, reconstitutes rapidly 1
• Cryoprecipitate: 2 pools (10 units) = ~4 g fibrinogen, or 50 mg/kg for weight-based dosing 1, 8
• No mortality difference between products in available trials 1, 6

Critical Pitfalls to Avoid:

• Do not wait for laboratory results in actively bleeding patients – use viscoelastic testing or empiric dosing 6, 2
• Do not use prothrombin time-derived fibrinogen assays – they show wide variation and discrepancies with Clauss assays 3
• Do not give fresh frozen plasma (FFP) as primary fibrinogen replacement – it provides insufficient fibrinogen concentration and causes volume overload 1
• Monitor for rebound hyperfibrinogenemia – levels typically rebound within 48 hours post-trauma and may contribute to thrombotic events 2

---

Management of Hyperfibrinogenemia

Elevated fibrinogen is an acute phase reactant and independent cardiovascular risk marker; treat the underlying inflammatory or thrombotic condition rather than the fibrinogen level itself. 4, 5

Understanding Elevated Fibrinogen:

• Normal range: 2.0-4.0 g/L 4
• Fibrinogen rises during inflammation, infection, trauma, and cardiovascular disease 4, 5
• In acute coronary syndromes, elevated fibrinogen independently predicts both short-term and long-term mortality 4

Management Approach:

Cardiovascular Risk Assessment:

• Recognize elevated fibrinogen as an independent thrombotic risk factor that strengthens (not contradicts) indications for anticoagulation 4
• Continue therapeutic anticoagulation as indicated by the primary condition (e.g., atrial fibrillation, VTE) 4
• Do not adjust anticoagulant doses based on fibrinogen levels – monitor standard parameters (INR for warfarin, anti-Xa for DOACs) 4

Inflammatory Conditions:

• Treat the underlying inflammatory disease (infection, autoimmune disorder, malignancy) 4
• Fibrinogen will normalize as inflammation resolves 4

Special Population – Pregnancy:

• Physiological elevation is expected and normal – fibrinogen reaches 3.7-6.2 g/L in third trimester 4
• No intervention required for elevated fibrinogen alone in pregnancy 1, 4
• Exception: In congenital dysfibrinogenemia type 3B (thrombotic variants), start thromboprophylaxis at pregnancy confirmation 1

When NOT to Treat Hyperfibrinogenemia:

• Do not use fibrinogen levels to guide anticoagulation intensity 4
• Do not empirically anticoagulate based solely on elevated fibrinogen without standard thrombotic risk assessment 4
• Do not attempt to "lower" fibrinogen pharmacologically – no evidence supports this approach 4, 5

Monitoring Strategy:

• In patients on anticoagulation with elevated fibrinogen, monitor standard coagulation parameters (INR, anti-Xa) rather than fibrinogen 4
• Assess cardiovascular risk using validated tools (CHADS₂-VASc, Wells score) rather than fibrinogen alone 4

---

Congenital Fibrinogen Disorders – Special Considerations

Pregnancy Management in Congenital Hypofibrinogenemia:

Women with afibrinogenemia or severe hypofibrinogenemia require preconception fibrinogen replacement targeting trough levels ≥1.0 g/L throughout pregnancy, increasing to ≥1.5 g/L during labor/delivery. 1

• Weekly fibrinogen measurements initially, then monthly to maintain targets 1
• Scheduled delivery in third trimester with multidisciplinary team availability 1
• Maintain ≥1.5 g/L for 3 days post-vaginal delivery, 5 days post-cesarean 1
• Add LMWH thromboprophylaxis until discharge when on fibrinogen replacement 1

Dysfibrinogenemia Type 3B (Thrombotic Variants):

• Start thromboprophylaxis at pregnancy confirmation 1
• Continue for 6 weeks postpartum 1
• Systematic fetal growth monitoring recommended 1

1, 4, 8, 6, 3, 9, 5, 2, 7